Nervous System Diseases

All Conditions

Symptoms and General Pathology

Substance Related Disorders

Rare Diseases

Peripheral Nervous System Diseases

Pain

Neurotoxicity Syndromes

Syndrome

Neuromuscular Diseases

Poisoning

Chemically-Induced Disorders

Treatment of chronic neuropathic pain with the MC5-A device

questionnaire administration

ECOG Common Toxicity Criteria for Sensory Neuropathy scale

Sensory Neuropathy Scale instrument

Uniscale 0-100 scale global quality of life

Quality of Life instrument

MC5-A Scrambler device

Thomas J. Smith, MD

RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.

PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy.

OBJECTIVES:

Primary

* To determine if MC5-A Scrambler therapy will improve the pain associated with chemotherapy-induced peripheral neuropathy in cancer patients by 20%.

Secondary

* To evaluate the effect of MC5-A therapy on specific pain and neuropathy scales.
* To evaluate the effect of MC5-A therapy on overall quality of life.
* To evaluate the effect of MC5-A therapy on other pain drugs used.
* To evaluate the toxicities of MC5-A therapy.

OUTLINE: Patients undergo gel electrode application on the skin in the most pain-free of the pain-affected area. Patients undergo treatment with the MC5-A Scrambler machine over 60 minutes once daily on days 1-10. On day 1, the treatment intensity is increased every 10 minutes to the maximum intensity individually bearable by the patient without any input of pain or discomfort. The patient should feel the disappearance of the pain during treatment as a sign that the proper nerve pathway(s) has (have) been correctly identified. Subsequent treatments begin at the highest intensity tolerated at the previous treatment. Patients with no improvement after 3 treatments discontinue treatment.

Patients complete questionnaires about symptoms, pain, and quality of life periodically.

After completion of study treatment, patients are followed up at 2 and 4 weeks, monthly for 3 months, and at 6 months.

Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy

The Efficacy of MC5-A ("Scrambler") Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial

Change in Neumeric Rating Score for Pain as measured by a Numeric Pain Rating scale between day 0 to day 15.

Scale is 0 (none) to 10 (severe)

Change on pain and neuropathy as measured by the Eastern Cooperative Oncology Group (ECOG) Common Toxicity Criteria for Sensory Neuropathy scale,0=none to 4=paralysis; the World Health Organization (WHO) Classification Scale, 0=none to 4=paralysis; and the Brief Pain Inventory-Short Form, 0=none to 4=most intense pain imaginable. Scores will be averaged.

The change in overal equivalent doses (all narcotic doses will be converted to morphine oral equivalent doses ie as mg/24hours. (All opiates taken will be recorded for the full 24 hours preceding the visit or phone call. All opiates will be converted to the pnmorphine equivalent using the Morphine oral dose equivalents (MOED). The total MOEDs taken during the 24 hours will be the sum of all opiates taken) used before intervention

Change on global quality of life. The global quality of life will improve as measured by the Uniscale Linear Analog Scale Assessment (LASA) quality of life scale 0=as bad as it can be to 10=as good as it can be. Scores will be averaged.

National Cancer Institute (NCI)

Virginia Commonwealth University

MC5-A Scrambler Instrument

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

Thomas J. Smith, MD, FACP

Patients treated with the MC5-A device for chronic chemotherapy-induced peripheral neuropathy

MC5-A Pain Treatment Device

Patients treated with MC5A devise for 10 consectuvive days

Spots Global Cancer Trial Database for sensory neuropathy scale instrument